What is B. Riley’s Forecast for KYMR FY2025 Earnings?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – B. Riley issued their FY2025 earnings per share estimates for Kymera Therapeutics in a research note issued on Monday, March 3rd. B. Riley analyst K. Patel expects that the company will post earnings per share of ($3.95) for the year. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ FY2026 earnings at ($4.46) EPS, FY2027 earnings at ($5.62) EPS and FY2028 earnings at ($5.82) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million.

Several other equities research analysts also recently commented on the company. Leerink Partners reissued an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Friday, December 27th. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. HC Wainwright raised their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, February 28th. BMO Capital Markets began coverage on shares of Kymera Therapeutics in a research note on Friday, December 6th. They issued a “market perform” rating and a $55.00 target price on the stock. Finally, BTIG Research initiated coverage on shares of Kymera Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target for the company. Three research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $56.69.

Kymera Therapeutics Stock Up 3.3 %

Kymera Therapeutics stock opened at $31.70 on Wednesday. Kymera Therapeutics has a twelve month low of $29.07 and a twelve month high of $53.27. The company has a market capitalization of $2.06 billion, a P/E ratio of -13.55 and a beta of 2.22. The stock’s 50 day moving average is $38.42 and its 200 day moving average is $43.48.

Institutional Trading of Kymera Therapeutics

Several hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP increased its stake in Kymera Therapeutics by 14.9% during the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock worth $213,514,000 after acquiring an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC increased its position in shares of Kymera Therapeutics by 14.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after purchasing an additional 650,000 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in Kymera Therapeutics during the 4th quarter valued at $23,856,000. Boxer Capital Management LLC bought a new stake in Kymera Therapeutics in the fourth quarter worth $17,098,000. Finally, Jennison Associates LLC boosted its stake in Kymera Therapeutics by 85.8% during the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock worth $37,754,000 after buying an additional 368,394 shares during the period.

Insiders Place Their Bets

In other news, insider Ellen Chiniara sold 2,241 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares in the company, valued at $2,438,588.25. This trade represents a 2.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,788 shares of company stock worth $455,202. Corporate insiders own 15.82% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.